Evaluation of <i>JAK2</i><sup>V617F</sup> in B and T Cell Neoplasms: Identification of <i>JAK2</i><sup>V617F</sup> Mutation of Undetermined Significance (JMUS) in the Bone Marrow of Three Individuals

Abstract

These findings suggest that JAK2(V617F) arises in the bone marrow of individuals before clinical manifestation of any myeloid disorders. Presence of JAK2(V617F) in bone marrow might therefore increase the risk of future MPD development, just as monoclonal gammopathy of undetermined significance (MGUS) increases the risk of multiple myeloma. We term this phenomenon 'JAK2(V617F) of undetermined significance' (JMUS). Its clinical significance remains to be determined. To our knowledge, these findings represent the first identification of JAK2(V617F) in the bone marrow of patients without myeloid malignancies.